Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network [0.03%]
社区心血管危险因素控制措施的改进——来自ASH卡罗来纳州-乔治亚州分会、高血压计划和社区医生网络的报告更新
Brent M Egan,Daniel T Lackland,Priscilla Igho-Pemu et al.
Brent M Egan et al.
The prevalence of hypertension dictates that blood pressure must be managed effectively in primary care. The American Society of Hypertension (ASH) regional chapters and clinical hypertension specialists represent a positive response by ASH...
Trent A Hargens,Sharon M Nickols-Richardson,John M Gregg et al.
Trent A Hargens et al.
Obstructive sleep apnea (OSA) is characterized by repetitive partial and total collapse of the upper airway that induces stressful arousals throughout sleep to reestablish breathing. Although estimates vary, prevalence has been reported as ...
William C Cushman,Jan Basile
William C Cushman
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends a blood pressure (BP) goal of
Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial [0.03%]
降压药物应用现状：抗高血压和血脂异常治疗以预防心肌梗死试验的影响
Marty S Player,James M Gill,Heather Bittner Fagan et al.
Marty S Player et al.
This national study examines the impact of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on the prescribing of thiazide-type diuretics and other antihypertensive medications for patients with newly...
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension [0.03%]
厄贝沙坦氢氯噻嗪复方作为初始治疗迅速控制重度高血压的疗效和安全性
Joel M Neutel,Stanley S Franklin,Suzanne Oparil et al.
Joel M Neutel et al.
Severe hypertension is difficult to control. This prospective, randomized, double-blind, active-controlled, multicenter trial compared efficacy and safety of once-daily irbesartan/hydrochlorothiazide (HCTZ) combination therapy with irbesart...
Randomized Controlled Trial
Journal of clinical hypertension (Greenwich, Conn.). 2006 Dec;8(12):850-7; quiz 858-9. DOI:10.1111/j.1524-6175.2006.05676.x 2006
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension [0.03%]
卡维地洛每日一次制剂治疗高血压的疗效研究
Michael A Weber,George L Bakris,Elizabeth A Tarka et al.
Michael A Weber et al.
Beta-blockers with pharmacologic effects that differ from conventional agents might add to antihypertensive treatment options. This study evaluated a new once-daily formulation of the beta-/alpha1-blocker, carvedilol controlled-release (CR)...
Randomized Controlled Trial
Journal of clinical hypertension (Greenwich, Conn.). 2006 Dec;8(12):840-9. DOI:10.1111/j.1524-6175.2006.05696.x 2006
Blood pressure goals for hypertension guidelines: what is wrong with "optimal"? [0.03%]
高血压指南中的血压控制目标：“理想”何错之有？
Thomas D Giles
Thomas D Giles
Organ systems dependent on nitric oxide and the potential for nitric oxide-targeted therapies in related diseases [0.03%]
依赖一氧化氮的器官系统以及相关疾病的一氧化氮靶向治疗的潜力
Norman K Hollenberg
Norman K Hollenberg
Nitric oxide (NO) is a universal messenger molecule that plays diverse and essential physiologic roles in multiple organ systems, including the vasculature, bone, muscle, heart, kidney, liver, and central nervous system. NO is produced by 3...
The role of nitric oxide in erectile dysfunction: implications for medical therapy [0.03%]
一氧化氮在勃起功能障碍中的作用及其对医学治疗的意义
Arthur L Burnett
Arthur L Burnett
Erectile dysfunction is a common, multifactorial disorder that is associated with aging and a range of organic and psychogenic conditions, including hypertension, hypercholesterolemia, diabetes mellitus, cardiovascular disease, and depressi...
R Preston Mason,John R Cockcroft
R Preston Mason
Increasing knowledge of the role of nitric oxide (NO) in physiology and disease has stimulated efforts to target the NO pathway pharmacologically. These therapeutic strategies include NO donors that directly or indirectly release NO and age...